ASCO Preview: Elotuzumab’s ‘Double Whammy’ Mechanism Hits Hard In Myeloma
This article was originally published in The Pink Sheet Daily
Executive Summary
Lead investigator for Bristol/AbbVie’s Phase III ELOQUENT trial of elotuzumab in myeloma says PFS curves are reminiscent of PD-1 inhibitors, expects overall survival benefit to be evident soon.